Matthew Harlin

4PUBLICATIONS
14CO-AUTHORS
Instrumental methods (excl. immunological and bioassay methods)Pharmaceutical delivery technologiesToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 14, 2023
Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison.

Matthew Harlin, Craig Chepke, Frank Larsen

|Jun 05, 2023
Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.

Roger S McIntyre, Pedro Such, Murat Yildirim

|Mar 24, 2023
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.

Matthew Harlin, Murat Yildirim, Pedro Such

|Aug 19, 2021
An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection.

Yanlin Wang, Xiaofeng Wang, Matt Harlin

Pageof 1

Frequent Collaborators

4 joint publications

Jessica Madera-McDonough

3 joint publications

Murat Yildirim

3 joint publications

Pedro Such

3 joint publications

Frank Larsen